Bottom line
RYCFX vs IBB: the short answer
RYCFX (Biotechnology Fund) and IBB (iShares Biotechnology ETF) are both mutual funds.
But IBB is far broader, holding 254 positions to 74 for RYCFX, so beyond the top names it adds exposure RYCFX doesn't have.
IBB is cheaper at 0.44% vs 2.38% — a difference of $194 a year per $10,000 invested.
Over five years, RYCFX returned +3.0% a year vs +2.5% for IBB.
Updated Nov 19, 2026
RYCFX vs IBB side by side
| RYCFX | IBB | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Guggenheim | iShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.38% | 0.44% |
| Annual cost per $10k | $238 | $44 |
| 10-yr cost on $10k (prospectus) | $2,763 | $555 |
| Max front load | 0% | None |
| 12b-1 fee | 1% | 0% |
| 1-yr return | +28.4% | +28.0% |
| 5-yr return (annualized) | +3.0% | +2.5% |
| 10-yr return (annualized) | +4.8% | +4.4% |
| Best quarter | +28.0% | +26.8% |
| Worst quarter | −22.7% | −22.9% |
| Net assets (fund) | $136.8M | $5.9B |
| Number of holdings | 74 | 254 |
| Portfolio turnover | 75% | 27% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYCFX | IBB | Difference |
|---|---|---|---|
| 2025 | +29.4% | +28.0% | +1.4% |
| 2024 | −1.7% | −2.4% | +0.7% |
| 2023 | +5.0% | +3.6% | +1.4% |
| 2022 | −13.9% | −13.6% | −0.3% |
| 2021 | +0.8% | +1.0% | −0.2% |
| 2020 | +20.9% | +25.9% | −5.0% |
| 2019 | +23.8% | +24.8% | −1.0% |
| 2018 | −9.9% | −9.1% | −0.8% |
| 2017 | +28.4% | +21.2% | +7.2% |
| 2016 | −20.3% | −21.5% | +1.2% |
Source: Fund prospectus bar charts
Holdings overlap
16 of RYCFX's top 25 holdings also appear in IBB's top 25.
| Holding | RYCFX | IBB |
|---|---|---|
| Amgen Inc | 5.05% | 7.50% |
| Gilead Sciences Inc | 4.49% | 7.52% |
| Vertex Pharmaceuticals Inc | 4.32% | 7.66% |
| Regeneron Pharmaceuticals Inc | 2.93% | 5.70% |
| Alnylam Pharmaceuticals Inc | 2.36% | 5.68% |
| Beone Medicines Ltd | 2.17% | 2.11% |
| Moderna Inc | 2.15% | 0.88% |
| Biogen Inc | 2.13% | 2.03% |
| Natera Inc | 2.12% | 2.11% |
| Illumina Inc | 1.94% | 1.41% |
| Insmed Inc | 1.79% | 2.95% |
| United Therapeutics Corp | 1.72% | 1.82% |
| Incyte Corp | 1.62% | 1.62% |
| Neurocrine Biosciences Inc | 1.52% | 1.34% |
| Argenx Se | 1.48% | 3.15% |
Source: SEC Form N-PORT
RYCFX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
FAQ
What is the difference between RYCFX and IBB?
Which is cheaper, RYCFX or IBB?
Should I own both RYCFX and IBB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.